In this study they did PSMA PET/CT to evaluate response 6 weeks after the 1st treatment.
The PSA response was evaluated 3 to 4 weeks after the treatment.
" Biochemical response to treatment was assessed according to the Prostate Cancer Working Group 3 criteria (PCWG3). According to the criteria, partial response was a >50% decline in PSA from the baseline with confirmation after 3 - 4 weeks, and a >25% increase in PSA level above the baseline was deemed biochemical disease progression"
However, most patients had a decline in PSA at 8 weeks after treatment.
"After the initial cycle of 225Ac-PSMA-617 TAT at a median of 8 weeks, 25/28 (89%) patients experienced any PSA decline; interestingly, 7 (25%) patients experienced remarkable >50% PSA decline even after the first cycle of TAT."
Hi Tall-Allen, that's what I concern ... we had a FDG PET before Ac225, and showed negative on Neuroendocrine, but doctor said, based on biospy from my dad's liver mets, he might be not benefit from Ac225. I haven't gotten the full report so I don't know the reason behind.
NEPC is rare, but there are other types of PCa that do not express PSMA. With an SUVmax of 28, and negative FDG, there should be some benefit. Maybe a PSMA PET scan will show some reduction.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.